[Form 4] Black Diamond Therapeutics, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Raman Prakash, a non-employee director of Black Diamond Therapeutics, Inc. (BDTX), elected to receive 3,843 shares of the issuer's common stock in lieu of cash for annual director compensation. The shares were issued on 09/19/2025 under the company’s Fifth Amended and Restated Non-Employee Director Compensation Policy. After the issuance, the reporting person beneficially owned 26,362 shares. The reported per-share price of $3.35 reflects the closing market price on 09/18/2025. The Form 4 was signed by an attorney-in-fact on 09/22/2025.

Positive

• Director elected equity in lieu of cash, aligning executive interests with shareholders by receiving 3,843 shares under the company compensation policy

Negative

• None.

Insights

Financial Analyst

TL;DR: Director elected stock for compensation, adding 3,843 shares; transaction appears routine and not materially dilutive.

This is a standard director compensation election rather than a market purchase or sale. The issuance of 3,843 shares increased the reporting person’s beneficial ownership to 26,362 shares. The price shown, $3.35, is the prior trading-day closing price and is used for disclosure; it does not indicate a market transaction executed at that price. From a financial standpoint, the item is routine and unlikely to meaningfully affect share count or valuation for investors given the absolute share numbers disclosed.

Corporate Governance Expert

TL;DR: This Form 4 documents a compensation election under an established director policy; governance procedures appear to have been followed.

The shares were issued pursuant to the company’s Fifth Amended and Restated Non-Employee Director Compensation Policy, which supports using equity in lieu of cash for non-employee directors. The filing notes the election and provides the calculation basis for reporting (closing price on 09/18/2025). There is no indication of related-party conflicts, amendments, or atypical vesting terms disclosed in this Form 4.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Raman Prakash

(Last) (First) (Middle)

C/O BLACK DIAMOND THERAPEUTICS, INC.

ONE MAIN STREET, 14TH FLOOR

(Street)

CAMBRIDGE MA 02142

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Black Diamond Therapeutics, Inc. [ BDTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
09/19/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/19/2025		A(1)		3,843	A	$3.35(2)	26,362	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These shares were issued in accordance with the Issuer's Fifth Amended and Restated Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for annual services as a non-employee director of the Issuer.

2. The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on September 18, 2025.

	/s/ Brent Hatzis-Schoch, Attorney-in-Fact	09/22/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did the Form 4 for BDTX filed by Raman Prakash report?

The Form 4 reports that Raman Prakash elected to receive 3,843 shares of Black Diamond Therapeutics common stock on 09/19/2025, increasing beneficial ownership to 26,362 shares.

At what price were the shares reported on the BDTX Form 4?

The price reported is $3.35 per share, based on the closing market price on 09/18/2025.

Why were the shares issued to the director according to the filing?

The shares were issued pursuant to the issuer’s Fifth Amended and Restated Non-Employee Director Compensation Policy as an election in lieu of cash compensation.

How many shares did Raman Prakash own after the transaction on the BDTX Form 4?

After the reported issuance, Raman Prakash beneficially owned 26,362 shares of BDTX common stock.

When was the Form 4 for this transaction signed?

The Form 4 signature block shows authorization by an attorney-in-fact and the signature date of 09/22/2025.